ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 20.6
(-4.63%)
SEK 20.6
(-4.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.32 Million SEK | -60.84% |
| 2022 | 34.03 Million SEK | 193.16% |
| 2021 | 11.61 Million SEK | -52.24% |
| 2020 | 24.31 Million SEK | 22.86% |
| 2019 | 19.78 Million SEK | 56.37% |
| 2018 | 12.65 Million SEK | 20.53% |
| 2017 | 10.49 Million SEK | -10.54% |
| 2016 | 11.73 Million SEK | 16.19% |
| 2015 | 10.1 Million SEK | 222.22% |
| 2014 | 3.13 Million SEK | 44.07% |
| 2013 | 2.17 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 38.83 Million SEK | 14.77% |
| 2024 Q1 | 33.83 Million SEK | 153.88% |
| 2023 Q3 | 21.83 Million SEK | 43.51% |
| 2023 Q4 | 13.32 Million SEK | -38.97% |
| 2023 Q1 | 23.65 Million SEK | -30.5% |
| 2023 Q2 | 15.21 Million SEK | -35.67% |
| 2023 FY | 13.32 Million SEK | -60.84% |
| 2022 Q1 | 8.7 Million SEK | -25.0% |
| 2022 FY | 34.03 Million SEK | 193.16% |
| 2022 Q4 | 34.03 Million SEK | 57.4% |
| 2022 Q3 | 21.62 Million SEK | 51.26% |
| 2022 Q2 | 14.29 Million SEK | 64.19% |
| 2021 Q1 | 12.84 Million SEK | -47.15% |
| 2021 Q3 | 13.44 Million SEK | -12.39% |
| 2021 Q2 | 15.34 Million SEK | 19.39% |
| 2021 FY | 11.61 Million SEK | -52.24% |
| 2021 Q4 | 11.61 Million SEK | -13.62% |
| 2020 FY | 24.31 Million SEK | 22.86% |
| 2020 Q1 | 19.35 Million SEK | -2.16% |
| 2020 Q2 | 24.09 Million SEK | 24.46% |
| 2020 Q3 | 42.15 Million SEK | 74.96% |
| 2020 Q4 | 24.31 Million SEK | -42.33% |
| 2019 Q3 | 13.11 Million SEK | 1.38% |
| 2019 FY | 19.78 Million SEK | 56.37% |
| 2019 Q4 | 19.78 Million SEK | 50.89% |
| 2019 Q2 | 12.93 Million SEK | 1.05% |
| 2019 Q1 | 12.8 Million SEK | 1.16% |
| 2018 FY | 12.65 Million SEK | 20.53% |
| 2018 Q2 | 11.32 Million SEK | -7.08% |
| 2018 Q4 | 12.65 Million SEK | 13.81% |
| 2018 Q1 | 12.18 Million SEK | 16.08% |
| 2018 Q3 | 11.11 Million SEK | -1.81% |
| 2017 Q2 | 10.67 Million SEK | 0.04% |
| 2017 Q1 | 10.66 Million SEK | -9.1% |
| 2017 Q4 | 10.49 Million SEK | -2.18% |
| 2017 FY | 10.49 Million SEK | -10.54% |
| 2017 Q3 | 10.73 Million SEK | 0.57% |
| 2016 Q1 | 8.49 Million SEK | 0.0% |
| 2016 Q4 | 11.73 Million SEK | 11.43% |
| 2016 Q3 | 10.53 Million SEK | 213.24% |
| 2016 Q2 | 3.36 Million SEK | -60.4% |
| 2016 FY | 11.73 Million SEK | 16.19% |
| 2015 FY | 10.1 Million SEK | 222.22% |
| 2014 FY | 3.13 Million SEK | 44.07% |
| 2013 FY | 2.17 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 87.497% |
| Ziccum AB (publ) | 6.38 Million SEK | -108.641% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -464.985% |
| BioArctic AB (publ) | 139.5 Million SEK | 90.446% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 61.483% |
| Mendus AB (publ) | 51.22 Million SEK | 73.981% |
| Genovis AB (publ.) | 98.04 Million SEK | 86.407% |
| Intervacc AB (publ) | 21.68 Million SEK | 38.524% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 50.097% |
| Active Biotech AB (publ) | 13.4 Million SEK | 0.537% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 89.25% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 17.305% |
| Aptahem AB (publ) | 8.99 Million SEK | -48.125% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 67.381% |
| Kancera AB (publ) | 17.97 Million SEK | 25.865% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 71.139% |
| Fluicell AB (publ) | 8.91 Million SEK | -49.501% |
| Saniona AB (publ) | 86.08 Million SEK | 84.517% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -158.395% |
| Biovica International AB (publ) | 34.76 Million SEK | 61.665% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -14.227% |
| AcouSort AB (publ) | 10.37 Million SEK | -28.426% |
| Xintela AB (publ) | 14.01 Million SEK | 4.902% |
| Abliva AB (publ) | 16.78 Million SEK | 20.577% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 93.789% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -15.204% |
| OncoZenge AB (publ) | 1.69 Million SEK | -684.461% |
| Amniotics AB (publ) | 10.54 Million SEK | -26.368% |
| 2cureX AB (publ) | 2.93 Million SEK | -354.106% |
| CombiGene AB (publ) | 4.15 Million SEK | -220.693% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -201.13% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.149% |
| Camurus AB (publ) | 414.81 Million SEK | 96.787% |
| Corline Biomedical AB | 6.78 Million SEK | -96.318% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 78.278% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 30.453% |
| I-Tech AB | 16.2 Million SEK | 17.754% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.876% |
| Cyxone AB (publ) | 4.69 Million SEK | -183.937% |
| Biosergen AB | 5.08 Million SEK | -162.104% |
| Cantargia AB (publ) | 54.97 Million SEK | 75.754% |
| NextCell Pharma AB | 13.68 Million SEK | 2.638% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 81.45% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 3.221% |
| Nanologica AB (publ) | 79.32 Million SEK | 83.199% |
| SynAct Pharma AB | 51.83 Million SEK | 74.287% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -67.669% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -156.557% |
| LIDDS AB (publ) | 3.75 Million SEK | -254.846% |
| Lipum AB (publ) | 7.53 Million SEK | -76.811% |
| BioInvent International AB (publ) | 90.45 Million SEK | 85.265% |
| Alzinova AB (publ) | 9.33 Million SEK | -42.836% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 92.661% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -642.921% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 27.933% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -247.264% |
| Simris Alg AB (publ) | 148.93 Million SEK | 91.051% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 81.259% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.236% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -4.583% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -83.581% |